Rodent Immuno-Safety Models

De-risk drug development with early toxicity screening of immunotherapeutic compounds


In Vivo Models of irAE for Safety and Toxicity Screening of Immunotherapies

Study unique immune-related adverse events (irAEs) associated with immunotherapies, using HuGEMM™ and HuCELL™ human target knock-in models. The platforms feature humanized drug targets within a fully functional murine immune system, providing an ideal method for assessing the complex nature of on-target and off-target toxicities of human-specific immunotherapies.

Efficacy and toxicity of human-specific therapies can be assessed in the same animal, enabling determination of the optimal therapeutic window in the same species and providing quick, cost-effective, and robust data to guide future drug development work.

Benefits of the HuGEMM Platform for Safety and Toxicity Screening

  • Efficiently study the safety of a range of targets for human immunotherapies
  • Enable determination of therapeutic index in the same species by assessing both efficacy and toxicity
  • Improve cost effectiveness with onsite pathology/histopathology services, including IHC, ICC, and IF
  • Rapid study initiation for fast turnaround of robust results - study duration optimized to fit client and project needs

Focused Toxicology Analysis of Immunotherapeutic Agents

  • Immune checkpoint inhibitors
  • Immune checkpoint stimulators
  • Bi-specific antibodies
  • Antibody-drug conjugates (ADCs)

Available Models  

Sample Data